{"id":"NCT01015118","sponsor":"Boehringer Ingelheim","briefTitle":"LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer","officialTitle":"Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11-17","primaryCompletion":"2013-04-01","completion":"2016-09-15","firstPosted":"2009-11-18","resultsPosted":"2015-01-15","lastUpdate":"2017-12-07"},"enrollment":1366,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ovarian Neoplasms","Peritoneal Neoplasms"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"BIBF 1120","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]}],"arms":[{"label":"BIBF 1120","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.","primaryOutcome":{"measure":"PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.","timeFrame":"First drug administration to date of disease progression or death whichever occurs first , upto 29 months","effectByArm":[{"arm":"Nintedanib","deltaMin":17.2,"sd":null},{"arm":"Placebo","deltaMin":16.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0239"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":28},"locations":{"siteCount":281,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Italy","Netherlands","Norway","Poland","Portugal","Russia","Slovakia","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["37185961","26590673"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":157,"n":450},"commonTop":["Nausea","Diarrhoea","Alopecia","Neutropenia","Fatigue"]}}